Castration-Resistant Prostate Cancer

This is a type of prostate cancer that doesn't respond to treatments that lower testosterone levels, like castration. It means the cancer keeps growing even when the body's main male hormone is reduced or removed. Doctors then need to try other treatments to control the cancer.

Condition

What people with Castration-Resistant Prostate Cancer report

Every report comes from a Lived member, sent anonymously.

Have you tried Xtandi (Enzalutamide) for Castration-Resistant Prostate Cancer?

NameHow it went

About Castration-Resistant Prostate Cancer

What It Is

Castration-resistant prostate cancer (CRPC) is prostate cancer that keeps growing even though hormone therapy has lowered testosterone to the very low level expected after removal of the testicles. Most prostate cancers depend on testosterone to grow, so lowering it, with injections, pills or surgery, usually controls advanced cancer for a time. CRPC is the stage at which the cancer finds ways to progress despite that treatment. The word castration describes the testosterone level, not the treatment someone has had; most people with CRPC have taken medicines rather than had surgery. CRPC comes in two broad forms. In non-metastatic CRPC, the only sign of growth is a rising blood test, with no spread visible on standard scans. In metastatic CRPC, the cancer has spread beyond the prostate, most often to the bones. Older names such as hormone-refractory prostate cancer are misleading, because many of these cancers still respond to newer hormone-targeting medicines. CRPC matters because most deaths from prostate cancer happen after the disease reaches the metastatic castration-resistant stage, but several treatments can extend life and control symptoms at this point.

Causes & Risk Factors

CRPC is not a separate disease someone catches. It develops when prostate cancer that has been treated with long-term testosterone-lowering therapy adapts to that treatment. In many cases the cancer cells keep using the androgen receptor, the switch that testosterone normally turns on. They may make more of the receptor, develop changes that make it easier to switch on, or produce small amounts of hormone within the tumor. This is why medicines that block the receptor more strongly or cut off other sources of hormone can still work after standard hormone therapy has stopped controlling the cancer. Less often, part of the cancer stops relying on hormone signaling altogether and takes on a different, neuroendocrine form, which tends to behave more aggressively and may respond better to chemotherapy. Some people carry inherited changes in DNA repair genes such as BRCA1, BRCA2 or ATM, and these changes can also be found in tumor tissue. They do not mean anyone did something wrong, but they matter for treatment choices and, when inherited, for relatives.

How It's Diagnosed

The diagnosis rests on two findings: testosterone is confirmed to be at castrate level, and the cancer is still progressing. A castrate level is a testosterone below 50 nanograms per deciliter (ng/dL), and it should be checked by blood test before CRPC is diagnosed, because a cancer that grows while testosterone is not fully suppressed may simply need its hormone therapy adjusted. Progression is usually first seen in the PSA (prostate-specific antigen), a protein made by prostate cells that rises when the cancer is active. Guidelines look for a steady climb: three rises in a row, at least a week apart, with the PSA above 2 ng/mL. Progression can also be shown by new spots on scans. New symptoms alone are not enough to make the diagnosis, but they prompt testing. When there is no visible spread, the PSA doubling time (how many months it takes the PSA to double) helps judge risk: doubling in 10 months or less signals a higher chance of spread and is a reason to consider added treatment. Scans such as CT (computed tomography), bone scans and PSMA PET (an imaging test that lights up prostate-specific membrane antigen, a protein found on most prostate cancer cells) show whether and where the cancer has spread. People with metastatic CRPC should also be offered genetic testing of the tumor and an inherited (germline) blood or saliva test. Results such as a BRCA1 or BRCA2 change, or a mismatch repair defect, can open specific treatment options.

Treatment Options

Testosterone-lowering therapy is usually continued after CRPC develops, and other treatments are added to it. The goals are to extend life, delay spread and complications such as fractures, and keep pain and other symptoms under control. Choices depend on whether the cancer has spread, which treatments were used earlier, symptoms, overall health, genetic test results and personal priorities, ideally planned with a team that includes urology and oncology. For non-metastatic CRPC with a fast-rising PSA, adding a stronger androgen receptor blocker, apalutamide (Erleada), darolutamide (Nubeqa) or enzalutamide (Xtandi), delayed visible spread by about two years on average in large trials, and all three have also been shown to help people live longer. Fatigue is common. Enzalutamide and apalutamide raise the risk of falls, fractures and high blood pressure, while darolutamide did not show these increases in its main trial. For metastatic CRPC, several treatments have each been shown in large trials to extend survival, typically by several months on average compared with the alternative tested, and many also delay pain and decline in quality of life: Hormone-targeting pills: abiraterone (Zytiga), which blocks hormone production elsewhere in the body and is taken with the steroid prednisone, and enzalutamide. Abiraterone can raise blood pressure, lower potassium and affect the liver, so it needs regular blood tests. Guidelines generally advise against moving straight from one of these medicines to the other, because the second tends to help less. Chemotherapy: docetaxel, given by vein every few weeks, can lengthen life and ease pain; cabazitaxel is used after docetaxel. Lowered white blood cell counts, which raise infection risk, are the main trade-off. Radiation-based medicines: radium-223 (Xofigo) targets cancer in bone and also reduced fractures and spinal cord problems in its trial; lutetium-177 PSMA-617 (Pluvicto) delivers radiation to cells carrying the PSMA protein and is used after hormone-targeting pills, either after chemotherapy or, for some people, before it, when a PSMA scan shows the cancer takes it up. Treatments matched to gene changes: PARP inhibitors, pills that block a DNA repair enzyme these cancers come to rely on, such as olaparib (Lynparza), used alone or combined with a hormone-targeting pill, for cancers with BRCA1, BRCA2 or similar DNA repair changes, and immunotherapy with pembrolizumab (Keytruda) for the small group with mismatch repair defects. Sipuleucel-T (Provenge), a personalized immunotherapy made from a person's own blood cells, is an option when the cancer causes few or no symptoms. It often does not lower the PSA but has been shown to extend survival. Supportive care runs alongside all of these. Bone-strengthening drugs, denosumab or zoledronic acid, taken with calcium and vitamin D, reduce fractures and other bone complications, though they rarely cause jaw bone damage, so dental care matters. Radiation aimed at a painful bone spot can relieve pain, and pain medicines and palliative care help with comfort at every stage. Clinical trials are worth asking about, since new treatments for this stage are being tested.

What to Expect

CRPC is a long-term, serious stage of prostate cancer, and its course varies widely. Someone with non-metastatic CRPC may feel well for years, with the main sign of the disease being PSA results. Metastatic CRPC is usually managed as a sequence of treatments: one is used until tests or symptoms show it has stopped working, then the next is chosen. How much daily life changes depends on where the cancer has spread and how each treatment is tolerated. Follow-up involves regular PSA and other blood tests, periodic scans and visits to review side effects. Long-term testosterone suppression itself brings hot flashes, lower sex drive, erectile problems, fatigue and thinning bones, and these effects deserve attention rather than silent endurance. Bone health care and attention to mood, sleep and physical activity are part of good follow-up. If the cancer spreads to bone, pain may come and go and can usually be eased with targeted radiation and medicines. Palliative care, which focuses on comfort and quality of life, can be added alongside cancer treatment at any stage. Talking with family and the care team about goals and preferences while treatment is going well makes later decisions easier.

When to Seek Help

Raise a rising PSA, new tiredness or side effects that interfere with daily life at your next visit, and ask whether the plan should change. Contact your cancer care team promptly about new or worsening pain in the back, hips, ribs or other bones, since early treatment of a painful bone spot can relieve it and prevent a fracture. New weakness or numbness in the legs, difficulty walking, or loss of bladder or bowel control, especially with back pain, can mean the cancer is pressing on the spinal cord. This needs emergency care right away, because prompt treatment with steroids, radiation or surgery can prevent permanent paralysis.

Questions to Ask Your Doctor

  1. 1.Has my testosterone been confirmed to be at castrate level, and is my cancer considered non-metastatic or metastatic?
  2. 2.Which treatment do you recommend next, what benefit can I realistically expect, and what would we try after that?
  3. 3.Should my tumor and my blood be tested for gene changes like BRCA1 or BRCA2, and what would the results mean for my family?
  4. 4.What are we doing to protect my bones, and what symptoms should make me call you?
  5. 5.Is there a clinical trial or a palliative care team that could help me now?

Last reviewed • Oct 2026

Educational content, not medical advice.